Weight Regulation Affecting Patents (Class 514/4.8)
-
Patent number: 9399669Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.Type: GrantFiled: December 28, 2012Date of Patent: July 26, 2016Assignee: Acceleron Pharma Inc.Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
-
Patent number: 9260503Abstract: The present invention regards an insulin derivative comprising at least 2 albumin binding moieties, wherein said albumin binding moieties comprise fatty diacid substitutions and a method for preparing such an insulin derivative by acylation and/or reductive alkylation. The present invention also concern a pharmaceutical comprising such an insulin derivative.Type: GrantFiled: June 14, 2012Date of Patent: February 16, 2016Assignee: Novo Nordisk A/SInventors: Thomas Hoeg-Jensen, Peter Madsen, Jane Spetzler, Tina Moeller Tagmose
-
Patent number: 9139631Abstract: The present disclosure is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The fusion polypeptides of the disclosure include FGF23 or an active fragment thereof. In one embodiment, the fusion polypeptide comprises (a) a polypeptide comprising fibroblast growth factor 23 (FGF23), or a functionally active variant or derivative thereof, wherein FGF23 has a mutation at one or more of the positions Q156, C206 and C244; and (b) either a modified Fe fragment having decreased affinity for Fc-gamma-receptor and/or increased serum half-life, or a polypeptide comprising at least one extracellular subdomain of a Klotho protein, or a functionally active variant or derivative thereof; and, optionally (c) a linker. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23), or a functionally active variant or derivative thereof; and a modified Fe fragment, or a functionally active variant or derivative thereof.Type: GrantFiled: January 17, 2013Date of Patent: September 22, 2015Assignee: NOVARTIS AGInventors: David Glass, Shou-Ih Hu
-
Patent number: 9096645Abstract: Dipeptide analogs comprising a tryptophan (Trp) moiety coupled to a beta-sheet breaker moiety derived from alpha-aminoisobutyric acid (Aib) are disclosed. The dipeptide analogs exhibit an improved performance in inhibiting amyloid fibril formation, as compared to previously described dipeptides. Compositions containing the dipeptide analogs and uses thereof in treating amyloid-associated diseases and disorders are also disclosed.Type: GrantFiled: November 15, 2011Date of Patent: August 4, 2015Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Ehud Gazit, Yaniv Amir, Ludmila Buzhansky, Ulrich Abel, Anat Frydman-Marom
-
Publication number: 20150141327Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) variants, pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such variants.Type: ApplicationFiled: June 5, 2013Publication date: May 21, 2015Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
-
Publication number: 20150132321Abstract: The present invention relates to methods of inhibiting capillary endothelial (CE) cell migration, the formation of CE networks and angiogenesis, and uses thereof for the purpose of treating angiogenesis-related diseases and disorders, particularly when the diseases or disorders are directly related aberrant angiogenesis. Inhibition is achieved by inhibiting TRPV4 activity, such as the levels of TRPV4 expression, calcium influx through TRPV4, and/or the intracellular signaling from TRPV4 via ?1 integrin activation.Type: ApplicationFiled: November 7, 2014Publication date: May 14, 2015Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Donald E. Ingber, Charles K. Thodeti
-
Patent number: 9029321Abstract: Methods and compositions are presented for use in diagnostic, imaging or targeting of therapeutic agents to treat obesity/adiposity-associated disorders, where such as compositions and methods identify and use peptides to selectively target adipose tissue stromal cells in mammals, both in vitro and in vivo.Type: GrantFiled: March 30, 2012Date of Patent: May 12, 2015Assignee: Board of Regents of the University of TexasInventors: Mikhail G. Kolonin, Alexes Daquinag, Yan Zhang
-
Patent number: 9029320Abstract: Formulations and methods for weight loss and body contouring are disclosed. An illustrative formulation comprises human chorionic gonadotrophin (hCG) and resveratrol. An illustrative method for weight loss and body contouring comprises administering hCG and resveratrol sublingually.Type: GrantFiled: August 26, 2013Date of Patent: May 12, 2015Assignee: Red Mountain Med Spa, LLCInventors: Mark Bentz, Suzanne Bentz, Riccardo Roscetti, M. Socorro Parra Arenas
-
Publication number: 20150126438Abstract: The invention provides diagnostic and prognostic methods and methods of evaluating treatment protocols for disorders such as obesity, diabetes, metabolic syndrome, cancer and vascular disease by detecting the levels of a novel isoform of ChREBP, termed ChREBP ?. The invention also provides nucleic acids, proteins, reporter constructs based on ChREBP ? and methods of identifying one or more agents that modulate the expression of a ChREBP ? target gene.Type: ApplicationFiled: January 22, 2013Publication date: May 7, 2015Inventors: Mark A. Herman, Barbara B. Kahn
-
Patent number: 9023789Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analog of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: GrantFiled: September 24, 2013Date of Patent: May 5, 2015Assignee: Novo Nordisk A/SInventors: Kirsten Dahl, Lauge Schaeffer, Thomas Kruse
-
Publication number: 20150119320Abstract: A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) is disclosed. Pharmaceutical compositions comprising the reverse pegylated oxyntomodulin and methods of using same are also disclosed.Type: ApplicationFiled: January 8, 2015Publication date: April 30, 2015Inventors: UDI EYAL FIMA, OREN HERSHKOVITZ
-
Patent number: 9018159Abstract: The present invention provides pladin (plasma anti-diabetic nucb2 peptide) polypeptide and functional equivalent thereof that are useful for treating diabetes. The present invention provides a method of treating diabetes by administering to a subject nesfatin-1, pladin, or a functional equivalent thereof. The present invention also provides a method of treating diabetes by administering to subject plasmin inhibitors.Type: GrantFiled: August 28, 2013Date of Patent: April 28, 2015Assignee: Landing Biotech, Inc.Inventor: Jian-ning Liu
-
Publication number: 20150099695Abstract: Compositions and methods for treatment of obesity and/or Type II diabetes and related metabolic disorders are provided wherein the methods and treatments comprise an effective amount of an isolated and/or purified C1q/TNF-related Protein-9 (CTRP9) or a functional portion thereof, and a pharmaceutically acceptable carrier. Methods of screening for molecules which elevate levels of CTRP9 in vivo are also provided. The present inventors provide the first in vivo evidence linking CTRP9 to regulation of fat metabolism in liver and skeletal muscle via AMPK signaling pathway, and highlight its protective metabolic function in the context of HFD-mediated metabolic insults.Type: ApplicationFiled: May 28, 2013Publication date: April 9, 2015Inventors: Guang William Wong, Jonathan M. Peterson
-
Patent number: 8999926Abstract: A nutritional composition for infants comprises a protein source, a lipid source and a carbohydrate source wherein the lipid source includes at least 16 wt % linoleic acid and at least 2 wt % ?-linolenic acid expressed as a percentage of total fatty acid content in each case and in amounts such that the ratio of linoleic acid:?-linolenic acid is in the range from 1 to 10.Type: GrantFiled: March 6, 2013Date of Patent: April 7, 2015Assignee: Nestec S.A.Inventors: Catherine Mace, Olivier Kevork Aprikian, Etienne Pouteau
-
Publication number: 20150094257Abstract: The present invention relates to a method for preventing and/or treating visceral adiposity and/or to alter body fat distribution by administering a certain nutritional composition to a human subject with the age between 0 and 48 months, and preventing the occurrence of diseases later in life.Type: ApplicationFiled: November 25, 2014Publication date: April 2, 2015Inventors: Renate Maria Louise ZWIJSEN, Eline Marleen VAN DER BEEK, Gelske Speelmans, Eünther BOEHM
-
Publication number: 20150087585Abstract: Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.Type: ApplicationFiled: March 26, 2013Publication date: March 26, 2015Applicant: PFIZER INC.Inventors: Kay Ahn, Markus Boehm, Shawn Cabral, Philip A. Carpino, Kentaro Futatsugi, David Hepworth, Daniel W. Kung, Suvi Orr, Jian Wang
-
Publication number: 20150080294Abstract: The invention provides methods for treating obesity in a subject comprising administering an effective amount of catestatin (CST) or its equivalent to a subject afflicted with obesity so as to maintain an effective amount of circulating catestatin in the subject to promote lipolysis and oxidation of released fatty acids in both liver and adipose tissue, thereby, reducing adipose tissue weight and hence treating obesity in the afflicted subject.Type: ApplicationFiled: April 1, 2013Publication date: March 19, 2015Inventors: Sushil K. Mahata, Gautam K. Bandyopadhyay
-
Patent number: 8980843Abstract: Peptides are provided having leptin receptor agonist activity. The peptides are useful for treating obesity, type II diabetes, appetite control after bariatric surgery, insulin resistance, lipodystrophy and hypothalamic amenorrhea, obesity-related infertility, among other diseases and conditions related to leptin deficiency and/or leptin resistance.Type: GrantFiled: June 25, 2010Date of Patent: March 17, 2015Assignee: Temple University—of the Commonwealth System of Higher EducationInventor: Laszlo Otvos, Jr.
-
Publication number: 20150065419Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.Type: ApplicationFiled: October 28, 2014Publication date: March 5, 2015Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIESInventors: JOHAN W. JONKER, MICHAEL DOWNES, RONALD M. EVANS, JAE MYOUNG SUH
-
Patent number: 8957020Abstract: This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing obesity, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the animal or human subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing obesity.Type: GrantFiled: September 26, 2011Date of Patent: February 17, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Arnd Steuernagel, Karsten Eulenberg, Guenter Broenner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jaekel, Christoph Meyer
-
Publication number: 20150038402Abstract: The present application provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.Type: ApplicationFiled: October 21, 2014Publication date: February 5, 2015Inventors: DAVID PAUL FAIRLIE, LIGONG LIU, MEI KWAN YAU, JACKY YUNG SUEN, ROBERT REID
-
Publication number: 20150038404Abstract: This invention relates to novel macrocyclic compounds (e.g., those delineated in the formulae herein), pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of the protease elastase.Type: ApplicationFiled: February 22, 2013Publication date: February 5, 2015Inventors: Hendrik Luesch, Valerie J. Paul, Lilibeth A. Salvador
-
Patent number: 8946146Abstract: The present invention provides a method of modulating appetite and/or body weight in a subject, said method comprising administering to said subject an effective amount of a MIC-1-modulating agent, wherein said agent increases or decreases the amount of MIC-1 present in said subject, or inhibits or enhances the biological activity of MIC-1 present in said subject.Type: GrantFiled: November 5, 2010Date of Patent: February 3, 2015Assignee: St Vincent's Hospital Sydney LimitedInventors: Samuel Norbert Breit, Asne Rhoda Bauskin
-
Publication number: 20150030595Abstract: The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.Type: ApplicationFiled: January 3, 2013Publication date: January 29, 2015Inventors: Dong Hee Lee, Bum Chan Park, Jae Eun Park, Myeong Hee Jang, Seok Ho Yoo, Hye Nan Kim
-
Publication number: 20150030594Abstract: The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I? (SEQ ID NO: 1): or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor.Type: ApplicationFiled: July 21, 2014Publication date: January 29, 2015Applicant: NOVARTIS AGInventors: Jun YUAN, Frederic ZECRI, Philipp GROSCHE, Hongjuan ZHAO, Andrei GOLOSOV, Kayo YASOSHIMA, David Thomas PARKER, Eric PETERS, Aimee Richardson USERA, Shari Lynn CAPLAN, Aaron KANTER, Changgang LOU, Carla Guimaraes
-
Publication number: 20150031605Abstract: The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18, wherein each of A11, A12, and A13 is independently absent, an amino acid, or an amino protecting group; each of A15, A16, A17, and A18 is independently absent or an amino acid; and A14 is a serine conjugated with a —C(O)C1-C20alky or a diaminopropionic acid conjugated with a —C(O)C1-C20alkyl group, provided that at least one of A11, A12, or A13 is present.Type: ApplicationFiled: October 2, 2014Publication date: January 29, 2015Inventors: Cyril Y. BOWERS, David H. COY, Simon J. HOCART, Gloria S. TANNENBAUM
-
Publication number: 20150031604Abstract: The invention provides a cyclic polypeptide of Formula I (SEQ ID NO: 1): X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13??I or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X3, X4, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor.Type: ApplicationFiled: July 21, 2014Publication date: January 29, 2015Applicant: NOVARTIS AGInventors: Frederic ZECRI, Philipp GROSCHE, Kayo YASOSHIMA, Hongjuan ZHAO, Jun Yuan, Aimee Richardson USERA, Changgang LOU, Aaron KANTER, Alexandra Marshall BRUCE, Carla Giumaraes
-
Patent number: 8940689Abstract: The present disclosure relates to a weight-loss composition including protein and fat and methods of use. The weight loss composition is substantially free of carbohydrates. The composition induces body weight loss when administered to a subject as the only source of nutrition for at least 12 hours.Type: GrantFiled: August 20, 2012Date of Patent: January 27, 2015Assignee: European Ketogenic Weight Loss Clinics LLCInventor: Oliver R. Di Pietro
-
Publication number: 20150023960Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.Type: ApplicationFiled: March 8, 2013Publication date: January 22, 2015Inventors: Darrin Anthony Lindhout, Peng Zhang, Thomas Frederick Parsons
-
Publication number: 20150011468Abstract: Casein compositions for increasing the rate of gastric emptying following ingestion of the composition, increasing the digestibility of a protein composition, or increasing the rate of delivery of amino acids to the blood, or for increasing the blood serum concentration of free leucine in a subject, preferably to substantially the same level as whey protein, the casein being about 10 to about 100% calcium depleted, having a degree of hydrolysis less than about 1% and having an unmodified phosphorylation pattern.Type: ApplicationFiled: March 11, 2013Publication date: January 8, 2015Applicant: FONTERRA CO-OPERATIVE GROUP LIMITEDInventors: Aaron Calvin FANNING, Hasmukh Ambalal PATEL, Johannes SCHALK, Ramon Stafford HALL, Roger Richard SCHWARZENBACH, Sergey Yevgenievich UKRAINTSEV
-
Publication number: 20150010508Abstract: The present invention provides methods and kits for treating diseases and conditions associated with impaired pancreatic function. The present invention further provides methods of stimulating islet cell neogenesis and stimulating islet cell differentiation from progenitor cells.Type: ApplicationFiled: July 21, 2014Publication date: January 8, 2015Inventors: Claresa S. Levetan, Loraine V. Upham
-
Publication number: 20150011466Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the it intracellular loop and domain of the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as cardiovascular diseases, (e.g., hypertension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.Type: ApplicationFiled: January 9, 2013Publication date: January 8, 2015Inventors: Thomas J. McMurry, Richard J. Looby
-
Patent number: 8920819Abstract: Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or animal body also form part of the invention. It is preferred that the drug is delivered to the brain.Type: GrantFiled: August 31, 2012Date of Patent: December 30, 2014Assignee: University College LondonInventors: Ijeoma Uchegbu, Aikaterini Lalatsa, Andreas Schatzlein
-
Patent number: 8921310Abstract: The present invention relates to an agent for improving lipid metabolism, a food/drink, and a feed, containing ?s-casein as an active ingredient thereof. In addition, the present invention relates to an agent for suppressing body weight gain, an agent for reducing body fat, and an agent for reducing blood lipid, containing the agent for improving lipid metabolism.Type: GrantFiled: June 5, 2007Date of Patent: December 30, 2014Assignee: Morinaga Milk Industry Co., Ltd.Inventors: Yuuki Somoto, Masayuki Ikeda
-
Patent number: 8906849Abstract: The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.Type: GrantFiled: April 8, 2013Date of Patent: December 9, 2014Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Odile Esther Levy, Carolyn M. Jodka, Soumitra S. Ghosh, David G. Parkes, Richard A. Pittner, Lawrence J. D'Souza, John S. Ahn, Kathryn S. Prickett, Jonathan David Roth, Sean H. Adams
-
Patent number: 8906851Abstract: Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.Type: GrantFiled: December 7, 2012Date of Patent: December 9, 2014Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Mark Fineman, Leigh MacConell, Kristin Taylor
-
Publication number: 20140348942Abstract: The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including inflammatory bowel disease (IBD), diverticulitis, colon cancer, an inflammatory disorder, obesity, congestive heart failure, benign prostatic hyperplasia (BPH), pain, salt retention or fluid retention.Type: ApplicationFiled: June 8, 2012Publication date: November 27, 2014Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Mark G. Currie, Daniel P. Zimmer, Angelika Fretzen, Marco Kassler, Brian M. Cali
-
Publication number: 20140342976Abstract: The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-? superfamily. According to the invention, an exemplary bioactive agent is BMP-7 The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the site of intravascular delivery of the bioactive agent.Type: ApplicationFiled: March 17, 2014Publication date: November 20, 2014Applicant: Stryker CorporationInventors: Mary Elizabeth Pecquet Goad, Denis Schrier, Allen Richard Pierce
-
Patent number: 8883721Abstract: The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18 (SEQ ID NO: 93), wherein each of A11, A12, and A13 is independently absent, an amino acid, or an amino protecting group; each of A15, A16, A17, and A18 is independently absent or an amino acid; and A14 is a serine conjugated with a —(O)C1-C20alky or a diaminopropionic acid conjugated with a —C(O)C1-C20alkyl group, provided that at least one of A11, A12, or A13 is present.Type: GrantFiled: May 12, 2010Date of Patent: November 11, 2014Assignees: McGill University, The Administrators of the Tulane Educational FundInventors: Cyril Y. Bowers, David H. Coy, Simon J. Hocart, Gloria S. Tannenbaum
-
Publication number: 20140328782Abstract: The present invention relates to a peptide inhibiting a matrix metalloproteanases activity and use thereof. The peptide inhibiting a matrix metalloproteanases activity exhibits an excellent efficacy of improving the condition of skin by directly inhibiting the matrix metalloproteanases activity. In addition, a composition containing the peptide of the invention has excellent bioactivities of inhibiting the activity of hyaluronic acid degrading enzymes, adipogenesis in fat cells, angiogenesis, and the like, thereby being useful for the treatment of various disease such as anti-obesity, anti-cancer, anti-inflammation, and the like, and skin permeability is excellent due to the small size of the peptide, thereby being useful in various fields. The peptide of the invention having excellent activity and safety can be advantageously applied to drugs, quasi-drugs, and cosmetics.Type: ApplicationFiled: November 2, 2011Publication date: November 6, 2014Applicant: CAREGEN CO., LTD.Inventors: Young Ji Chung, Eun Mi Kim
-
Publication number: 20140329741Abstract: The present application includes a method for improving human and animal health comprising administering an effective amount of a linus cyclopeptide (LCP) extract from flaxseed to a subject in need thereof. Also included are feeds, foodstuffs, functional food compositions, natural product compositions nutraceuticals and food additive compositions comprising an LCP extract from flaxseed.Type: ApplicationFiled: December 19, 2012Publication date: November 6, 2014Inventors: Bernard Laarveld, Andrew A. Olkowski
-
Publication number: 20140328794Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.Type: ApplicationFiled: July 18, 2013Publication date: November 6, 2014Applicant: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Publication number: 20140322136Abstract: The present invention provides methods to reduce or inhibit weight gain by administering inhibitors of the SirT1 protein to a subject. Methods to identify such inhibitors are also disclosed.Type: ApplicationFiled: May 6, 2014Publication date: October 30, 2014Inventors: Yansong GU, Hongzhe LI
-
Publication number: 20140322302Abstract: Therapeutic peptides having guanylyl cyclase C agonist activity are disclosed. The therapeutic peptides are analogues of the E. coli STa peptide with non-natural amino acid, isosteric or D-amino acid substituents. The therapeutic peptides are useful in the treatment of chronic ideopathic constipation, inflammatory bowel disease, and other diseases. Pharmaceutical compositions comprising the therapeutic peptides are also disclosed.Type: ApplicationFiled: May 11, 2014Publication date: October 30, 2014Applicant: COMBIMAB, INCInventors: Henry Wolfe, Reinhard Ebner
-
Publication number: 20140315796Abstract: The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as metabolic syndrome, obesity, type II diabetes, fibrosis and cardiovascular diseases, whether they are used alone or in combination with other treatment modalities.Type: ApplicationFiled: July 27, 2012Publication date: October 23, 2014Applicant: The University of QueenslandInventors: David Fairlie, Ligong Liu, Mei-Kwan Yau, Jacky Yung Suen, Robert Reid, Rink-Jan Lohman, Abishek Venkatasubramania Iyer, Junxian Lim, Lindsay Charles Brown
-
Publication number: 20140315795Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a receptor which can be internalised by the cell in response to the binding of said selectivity agent. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of contrast agents to the cells for diagnostic purposes.Type: ApplicationFiled: October 25, 2013Publication date: October 23, 2014Inventors: Maria del Carmen CARMONA OROZCO, Andrés Montefeltro, Gabriel Alvarado Urbina, Analía Bortolozzi Biassoni, Raquel Revilla-Sanchez
-
Publication number: 20140308235Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.Type: ApplicationFiled: April 9, 2014Publication date: October 16, 2014Inventors: John S. Petersen, James Shanahan
-
Publication number: 20140301974Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.Type: ApplicationFiled: January 30, 2014Publication date: October 9, 2014Applicant: Amunix Operating Inc.Inventors: Volker Schellenberger, Joshua Silverman, Chia-Wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
-
Patent number: 8853152Abstract: Methods of spray drying are described.Type: GrantFiled: June 10, 2009Date of Patent: October 7, 2014Assignee: Vertex Pharmaceuticals IncorporatedInventors: Kevin Bittorf, Jeffrey Kastra, Filipe Gaspar
-
Patent number: 8853157Abstract: The present invention describes administering a GLP-1 agonist to treat obesity caused by the administration of an obesity-inducing drug.Type: GrantFiled: February 26, 2013Date of Patent: October 7, 2014Assignee: Novo Nordisk A/SInventors: Sanne Moeller Knudsen, Karin Rimvall